Until recently, how and which specific metabolic pathways regulate NAD levels has been unclear, despite its broad centrality to disease including age-related NAD decline, which is viewed as an underlying process of multiple conditions of aging. It is well known that NAD (nicotinamide adenine dinucleotide) is a cofactor of key enzymes in a healthy cell including glycolysis and multiple other critical redox reactions. TeneoFour aims to target the critical role of CD38 in cellular metabolic processes, particularly NAD metabolism. While we certainly valued TeneoTwo, central to our investment thesis in Ancora was also the potential of TeneoFour and TeneoTen - the ability to leverage the existing platform to address high unmet needs outside of oncology. Such a velocity of valuable deal-making, even in this market environment, underscores the value of the platform, quality of assets and the thoughtfulness behind the clinical strategies that the Ancora team pursued for TeneoTwo, and now, continues to leverage for TeneoFour and TeneoTen. Over the past 12 months, the same team behind Teneobio and Ancora have led three acquisitions - TeneoOne to Abbvie, Tenebio to Amgen, and now, TeneoTwo to AstraZeneca. While this transaction comes less than a month since Lightspeed’s investment in Ancora’s Series A, it is part of a longer narrative we described in a previous post. We congratulate both the Ancora and AstraZeneca teams on this achievement. To us, the acquisition ultimately expedites the path to improving patient lives across these serious areas of unmet clinical need. The acquisition will accelerate the development of TeneoTwo’s CD19/CD3 T-cell engager for B-cell malignancies, including large B-cell lymphoma and follicular lymphoma. Today, AstraZeneca announced its agreement to acquire TeneoTwo, a subsidiary of TBio which is managed by Ancora Biotech, for $100M upfront as part of a total transaction value of $1.265B including milestones. Ancora Biotech: TeneoTwo Acquisition & What’s Nextīy Galym Imanbayev and Jonathan MacQuitty
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |